leadf
logo-loader
viewCanntab Therapeutics Ltd

Canntab Therapeutics hits major milestone as company makes first delivery to MediPharm Labs

Canntab Therapeutics (CSE: PILL- OTCQB: CTABF) CEO Larry Latowski and CFO Richard Goldstein joined Steve Darling from Proactive with news the company has completed its first delivery of two of five SKU's ordered by MediPharm Labs.

Goldstein and Latowski tall about them taking this major step and why this validates all the works they have been doing over the years to get to this point.

Quick facts: Canntab Therapeutics Ltd

Price: 0.73 CAD

CSE:PILL
Market: CSE
Market Cap: $24.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Canntab Therapeutics received purchase order from Australia while also...

Canntab Therapeutics (CSE: PILL-OTCQB: CTABF) CFO Richard Goldstein joined Steve Darling from Proactive Vancouver with news the company has announced the launch of its suite of hard pill cannabinoid formulations in Australia with its partner CANN Global Ltd. Goldstein takes Proactive through...

on 10/26/2020

2 min read